TDC
IDXX icon

Thompson Davis & Co’s Idexx Laboratories IDXX Stock Holding History

Thompson Davis & Co’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-44
Closed -$7K – 1141
2017
Q2 		$7K Buy
44
+1
+2% +$162 0.01% 751
2017
Q1 		$7K Hold
43
– – 0.01% 805
2016
Q4 		$5K Buy
+43
New +$4.91K 0.01% 860

Other funds holding IDXX

Fundsmith LLP
Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Thompson Davis & Co's IDXX Position: Q3 2017 in Review

Thompson Davis & Co sold out of Idexx Laboratories (IDXX) in Q3 2017, closing a stake of 44 shares — an estimated $7K sold.

Thompson Davis & Co first reported a position in IDXX in Q4 2016 and held it in 3 quarters. The position peaked at $7K in Q2 2017. 573 funds tracked by Wall St. Rank hold IDXX as of Q3 2017.

  • Thompson Davis & Co reported no remaining Idexx Laboratories position as of Q3 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 44 Idexx Laboratories shares in Q3 2017, an estimated $7K.
  • Thompson Davis & Co first reported a position in Idexx Laboratories in Q4 2016 and held it in 3 quarters.
  • Thompson Davis & Co's Idexx Laboratories position peaked at $7K in Q2 2017.
  • 573 funds tracked by Wall St. Rank held Idexx Laboratories as of Q3 2017.

Based on Thompson Davis & Co's 13F filing for Q3 2017, filed 30 Oct 2017.